Close

News

Amgen’s full year 2012 revenues increased 11 percent to $17.3 billion

Amgen has announced financial results for the fourth quarter and full year of 2012. Key results include: For the full year, total revenues increased 11 percent to $17,265 million, with 9 percent product sales...

New drug protects against side effects of chemotherapy

A drug developed at Linköping University in Sweden protects against the side effects of cancer treatments while strengthening the effects on the tumour. An international drug evaluation is now starting up on a larger...

Takeda establishes new trading company and reinforces business structure in China

Takeda Pharmaceutical Company Limited ("Takeda") today announced the launch of a new trading company in China, Takeda (China) International Trading Co., Ltd. ("TCIT"), which will strengthen its business structure in China, and is an important step in the...

Potential new treatment for gastrointestinal cancers discovered

Researchers have identified a complex of proteins that promotes the growth of some types of colon and gastric cancers, and shown that medications that block the function of this complex have the potential to be developed into a...

Gene therapy cocktail shows promise in long-term clinical trial for rare fatal brain disorder

Results of a clinical trial that began in 2001 show that a gene therapy cocktail conveyed into the brain by a molecular special delivery vehicle may help extend the lives of children with Canavan disease, a rare and...

New cell-based system can screen drug candidates for cardiac toxicity

A new stem cell-derived system for screening experimental drugs for cardiotoxicity could identify dangerous side effects early in the development process, thereby potentially saving time, lives and money, according to Evan F. Cromwell, PhD, of Molecular Devices, LLC,...

Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing’s disease

Novartis announced that the US Food and Drug Administration (FDA) has approved Signifor® (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »